Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children

Pediatric Obesity

Volumn 9, Issue 2, 2014, Pages 81-91

  Ooi, S Q ^a,b   Chan, R M E ^b   Poh, L K S ^b   Loke, K Y ^b   Heng, C K ^b   Chan, Y H ^b   Gan, S U ^b   Lee, K O ^a   Lee, Y S ^b  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Adipokine; obese children; obesity; visfatin

Indexed keywords

ADENINE; CYTOSINE; GUANINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; THYMINE; CYTOKINE; GLUCOSE BLOOD LEVEL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ALLELE; ANTHROPOMETRY; ARTICLE; CARDIOMETABOLIC RISK; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAMPT GENE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC ANGIOPATHIES; DNA SEQUENCE; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; MORBID OBESITY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RISK ASSESSMENT; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHILD; CYTOKINES; DIABETIC ANGIOPATHIES; FEMALE; GENETIC VARIATION; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84920674401     PISSN: 20476302     EISSN: 20476310     Source Type: Journal    
DOI: 10.1111/j.2047-6310.2013.00149.x     Document Type: Article

References (36)

1. Bray GA, Bellanger T,. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109-117.
2. Galic S, Oakhill JS, Steinberg GR,. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139.
3. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
4. Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science 2007; 318: 565.
5. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
6. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134.
7. Araki S, Dobashi K, Kubo K, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16: 384-388.
8. Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2011; 91: 154-158.
9. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M,. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914.
10. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
11. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170.
12. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W,. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791.
13. Retnakaran R, Youn BS, Liu Y, et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69: 885-893.
14. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD,. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 107-117.
15. Bailey SD, Loredo-Osti JC, Lepage P, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006; 55: 2896-2902.
16. Tokunaga A, Miura A, Okauchi Y, et al. The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J 2008; 55: 205-212.
17. Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC,. Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med 2007; 35: 1290-1295.
18. Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 361-370.
19. Yan JJ, Tang NP, Tang JJ, et al. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. Clin Chim Acta 2010; 411: 26-30.
20. Wang LS, Yan JJ, Tang NP, et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep 2011; 38: 819-825.
21. Bottcher Y, Teupser D, Enigk B, et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006; 91: 2725-2731.
22. Zhang YY, Gottardo L, Thompson R, et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006; 14: 2119-2126.
23. Wang YS, Gao W, Li HF, et al. Mechanistic insights into the link between visfatin gene C-1535T polymorphism and coronary artery disease: an in vitro study. Mol Cell Biochem 2011; 363: 315-322.
24. Garcia-Bermudez M, Gonzalez-Juanatey C, Rodriguez-Rodriguez L, et al. Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 681-688.
25. Korner A, Bottcher Y, Enigk B, Kiess W, Stumvoll M, Kovacs P,. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism 2007; 56: 772-777.
26. Johansson LM, Johansson LE, Ridderstrale M,. The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 2008; 57: 1558-1562.
27. Liu P, Li H, Cepeda J, et al. Critical role of PBEF expression in pulmonary cell inflammation and permeability. Cell Biol Int 2009; 33: 19-30.
28. Lee YS, Kek BL, Poh LK, Saw SM, Loke KY,. Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children. J Pediatr Gastroenterol Nutr 2008; 47: 172-178.
29. Mei Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH,. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am J Clin Nutr 2002; 75: 978-985.
30. Alemzadeh RLF,. Childhood obesity. In:, Lifshitz F, (ed.). Pediatric Endocrinology, 3rd edn. Marcel Dekker: New York, 1996, 22.
31. Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28: 1257-1263.
32. Report of the Second Task Force on blood pressure control in children-1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79: 1-25.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
34. Friebe D, Neef M, Kratzsch J, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyl transferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011; 54: 1200-1211.
35. Kolsgaard ML, Wangensteen T, Brunborg C, et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858-864.
36. Romanowska A, Lebensztejn DM,. [Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]. Pol Merkur Lekarski 2010; 28: 459-461.